Alexion Pharmaceuticals, Inc.

alexion.com

At Alexion, our mission is to serve patients and families affected by rare diseases. Since our founding, we have given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

VALGENESIS AND PHARMENG TECHNOLOGY PARTNER TO MODERNIZE AND DIGITIZE VALIDATION AND COMPLIANCE FOR GLOBAL PHARMA, BIOTECH, MEDICAL DEVICE

PRNewswire | June 07, 2023

news image

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and PharmEng Technology, a global ISO-certified consulting firm focused on life sciences, have partnered to provide a range of regulatory intelligence, GxP compliance, and digitized validation solutions for pharmaceutical, biotechnology, medical device, and nutraceutical companies across the globe. PharmEng Technology has staff all over the world serving companies of all sizes, prov...

Read More

SEVEN PHARMACEUTICAL STOCKS THAT STAND TO WIN BEYOND THE COVID-19 CHASE

InvestorPlace | July 15, 2020

news image

It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks. What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, while others are creating long-term solutions to major trends. This is especially true in the pharmaceutical and biotech spaces right now. Maybe it’s because the Kentucky Derby was postponed, but people are betting on ...

Read More

Business Insights

VIVERA ENTERS $23 BILLION TELEHEALTH INDUSTRY WITH PATENT ALLOWANCE FOR MDZONE

Vivera Pharmaceuticals, Inc. | April 25, 2022

news image

Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, "Self-Contained, Portable, Sanitization Device and Telemedicine Station," for the Company's MDZone platform from the United States Patent and Trademark Office. This Notice of Allowance indicates that the patent application has passed its examination for issuance. MDZone will be a HIPAA compliant, portable telemedicine sta...

Read More

DON'T CUT BACK ON ASTHMA MEDS DURING PANDEMIC, EXPERT ADVISES

Drugs | April 19, 2020

news image

Despite increased demand for inhalers in some parts of the United States, Americans with asthma shouldn't ration their medications during the coronavirus pandemic, the American Lung Association says. Rescue inhalers are in short supply in some areas because hospitals are giving albuterol to COVID-19 patients with severe symptoms to help them breathe, the group explained. Albuterol is a quick-relief medication used to treat shortness of breath and wheezing in people with asthma and some other...

Read More
news image

Pharma Tech

VALGENESIS AND PHARMENG TECHNOLOGY PARTNER TO MODERNIZE AND DIGITIZE VALIDATION AND COMPLIANCE FOR GLOBAL PHARMA, BIOTECH, MEDICAL DEVICE

PRNewswire | June 07, 2023

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and PharmEng Technology, a global ISO-certified consulting firm focused on life sciences, have partnered to provide a range of regulatory intelligence, GxP compliance, and digitized validation solutions for pharmaceutical, biotechnology, medical device, and nutraceutical companies across the globe. PharmEng Technology has staff all over the world serving companies of all sizes, prov...

Read More
news image

SEVEN PHARMACEUTICAL STOCKS THAT STAND TO WIN BEYOND THE COVID-19 CHASE

InvestorPlace | July 15, 2020

It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks. What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, while others are creating long-term solutions to major trends. This is especially true in the pharmaceutical and biotech spaces right now. Maybe it’s because the Kentucky Derby was postponed, but people are betting on ...

Read More
news image

Business Insights

VIVERA ENTERS $23 BILLION TELEHEALTH INDUSTRY WITH PATENT ALLOWANCE FOR MDZONE

Vivera Pharmaceuticals, Inc. | April 25, 2022

Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, "Self-Contained, Portable, Sanitization Device and Telemedicine Station," for the Company's MDZone platform from the United States Patent and Trademark Office. This Notice of Allowance indicates that the patent application has passed its examination for issuance. MDZone will be a HIPAA compliant, portable telemedicine sta...

Read More
news image

DON'T CUT BACK ON ASTHMA MEDS DURING PANDEMIC, EXPERT ADVISES

Drugs | April 19, 2020

Despite increased demand for inhalers in some parts of the United States, Americans with asthma shouldn't ration their medications during the coronavirus pandemic, the American Lung Association says. Rescue inhalers are in short supply in some areas because hospitals are giving albuterol to COVID-19 patients with severe symptoms to help them breathe, the group explained. Albuterol is a quick-relief medication used to treat shortness of breath and wheezing in people with asthma and some other...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us